Home PageBX.SCIENCECadio-EducationTrans-Immunization – Yale School of MedicineMRI at HARVARDAbout NYCC
transpx.gif (43 bytes)

 


Beginning with the first association between NYCC and Yale School of Medicine in 1990, a fount of information has poured forth to contribute to improvements in the investigation and clinical treatment of diseases of the cardiovascular system. The first association was a project that involved the investigation of the use of extra-corporeal photochemistry (ECP), known as photopheresis, developed in the early 1980’s, by Dr. Richard L. Edelson, now Professor and Chairman of Dermatology at Yale and Past Director, Yale Comprehensive Cancer Center. The study was titled, Photopheresis for the Therapy of Progressive Systemic Scleroderma: A disease affecting the Cardiovascular System. Impressive statistical evidence, gathered in that study, justified further clinical trials.

A second project involved the use of photopheresis to control the rejection of transplanted hearts. This study was so successful that it led to photopheresis being utilized in more than 150 cardiac treatment centers around the world where heart transplants are performed. A paper published in 1998 in The New England Journal of Medicine described how this new treatment protocol is more effective than conventional immunosuppression in preventing episodes of cardiac rejection. More importantly, further coronary artery disease in these transplanted hearts is markedly reduced.

A third project was a retrospective statistical study of sixty patients who had been treated with photopheresis for the treatment of cutaneous t-cell lymphoma, a common type of lymphoma. These patients, ranging in age from 55 to 80 were statistically compared to a group of patients who had not been treated with photopheresis. Evidence of disease including angina and myocardial infarction was looked for in these patients. Although statistics suggested that one in eight of these persons would have been expected to show evidence of cardiovascular disease, there were no such incidents present in the photopheresis treated group.

Through the year 2010, Photopheresis remains the leading immunotherapy approved by the U.S. Food and Drug Administration (FDA). Over 1.5 million patients worldwide have been treated with this therapy.

The current association between Yale School of Medicine and NYCC, following the original work with photopheresis, is the study of - Transimmunization: insights into the immune system. Monocytes in peripheral blood  are  activated by the forces encountered during ECP to differentiate into dendritic cells. Dendritic cells, in addition to possessing the ability to provoke immune responses, may allow for their control. It is conceivable that at some point, these cells may provide a means to create vaccines to treat certain types of cancer.

 

---------------------------------------------------------------------------------------------------------------------------------

To learn more about NYCC projects call us at (201) 569-8180, fax us at (201) 568-5571
or write to us at: 82 North Summit Street, Tenafly, NJ 07670.

 

Home | Bx Science | Cardio-Education | Trans-Immune at Yale | Mri at Harvard
About NYCC | Memorials


Copyright © NYCC 2000

9-bottom.jpg (5427 bytes)
transpx.gif (43 bytes)

Designed by Starhostmedia.com